OTCMKTS:VVUSQ

VIVUS Stock Forecast, Price & News

$0.12
+0.00 (+1.56 %)
(As of 12/11/2020)
Add
Compare
Today's Range
$0.11
Now: $0.12
$0.12
50-Day Range
$0.12
MA: $0.12
$0.12
52-Week Range
$0.07
Now: $0.12
$4.55
Volume103,000 shs
Average Volume937,537 shs
Market Capitalization$2.10 million
P/E RatioN/A
Dividend YieldN/A
Beta-3.25
VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatic cancer or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, nonalcoholic steatohepatitis, and bariatric surgery; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; and Alvogen Malta Operations (ROW) Ltd. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California. On July 7, 2020, VIVUS, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:VVUSQ
CUSIPN/A
CIKN/A
Phone650-934-5200
Employees59
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$69.76 million
Book Value($6.50) per share

Profitability

Net Income$-31,500,000.00

Miscellaneous

Market Cap$2.10 million
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

Headlines

VVUS Dec 2020 4.000 call
November 3, 2020 |  ca.finance.yahoo.com
Oil Search third quarter revenue plunges 48%
October 19, 2020 |  reuters.com
See More Headlines

MarketRank

Overall MarketRank

0.63 out of 5 stars

Medical Sector

1343rd out of 2,011 stocks

Pharmaceutical Preparations Industry

591st out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$0.12
+0.00 (+1.56 %)
(As of 12/11/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive VVUSQ News and Ratings via Email

Sign-up to receive the latest news and ratings for VVUSQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











VIVUS (OTCMKTS:VVUSQ) Frequently Asked Questions

What stocks does MarketBeat like better than VIVUS?

Wall Street analysts have given VIVUS a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but VIVUS wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is VIVUS's next earnings date?

VIVUS is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for VIVUS
.

Who are VIVUS's key executives?

VIVUS's management team includes the following people:
  • Mr. John P. Amos, CEO, Pres & Director (Age 53, Pay $556.2k)
  • Mr. Mark K. Oki, Sr. VP, CFO & Chief Accounting Officer (Age 51, Pay $422.2k)
  • Mr. John L. Slebir, Sr. VP of Bus. Devel., Gen. Counsel & Sec. (Age 55, Pay $632.7k)
  • Dr. Santosh T. Varghese, Sr. VP & Chief Medical Officer (Age 50, Pay $555.44k)
  • Ms. Deborah Larsen, Chief Strategy Officer - Commercial Operations

Who are some of VIVUS's key competitors?

What is VIVUS's stock symbol?

VIVUS trades on the OTCMKTS under the ticker symbol "VVUSQ."

How do I buy shares of VIVUS?

Shares of VVUSQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VIVUS's stock price today?

One share of VVUSQ stock can currently be purchased for approximately $0.12.

How much money does VIVUS make?

VIVUS has a market capitalization of $2.10 million and generates $69.76 million in revenue each year. The company earns $-31,500,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis.

How many employees does VIVUS have?

VIVUS employs 59 workers across the globe.

What is VIVUS's official website?

The official website for VIVUS is www.vivus.com.

Where are VIVUS's headquarters?

VIVUS is headquartered at 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008.

How can I contact VIVUS?

VIVUS's mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The company can be reached via phone at 650-934-5200 or via email at [email protected]


This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.